What's New The Case for MDMA's Approval Is Riddled With Problems
Jun 10, 2024
Debating MDMA's Approval for PTSD Treatment: FDA evaluating MDMA for PTSD, issues with trial data, concerns about therapy standardization, participant bias, and ongoing debate around effectiveness and ethics of this approach
AI Snips
Chapters
Transcript
Episode notes
MDMA for PTSD Faces Hurdles
- The FDA is considering approving MDMA-assisted psychotherapy for PTSD, but an advisory panel voted against it due to insufficient evidence.
- Concerns include biased reporting from participants, non-standardized therapy, and prior MDMA use.
Concerns about MDMA Trials
- The FDA advisors cited concerns about the MDMA trials like participants knowing if they received the drug or a placebo and inconsistencies in therapy.
- Other concerns include prior MDMA use by participants, duration of symptom relief, and side effect monitoring.
Veteran Advocate's Perspective
- Julianna Mercer, director of veteran advocacy, believes MDMA-assisted therapy saved her life and is crucial for addressing the veteran suicide epidemic.
- The committee's decision, she feels, overlooks the dire need for alternative PTSD treatments.